Article
FDA panel expresses concern over OTC OAB patch
Merck has confirmed that the FDA Nonprescription Drug Advisory Committee proposed that the FDA consider labeling modifications as part of its review of oxybutynin transdermal system (Oxytrol) as an over-the-counter treatment for overactive bladder in women.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Related Videos
Investigators compare trimodal therapy vs cystectomy in MIBC
Rethinking First-Line Treatments: Will BCG Continue to Be the Standard in NMIBC?
In the Pipeline: Novel Treatment Delivery Methods for NMIBC
Investigators assess ctDNA’s role in NMIBC
RX Review: Implementing mitomycin for LG-IR-NMIBC in clinical practice
RX Review: TURBT vs chemoablation for low-grade, intermediate-risk NMIBC
RX Review: A paradigm shift for low-grade, intermediate-risk NMIBC
RX Review: How mitomycin for intravesical solution works in treating LG-IR-NMIBC
RX Review: Redefining treatment for LG-IR-NMIBC
Vignesh Packiam, MD, on the MOA, dosing of detalimogene voraplasmid
Related Content
